LDS/Medical Tests/Prader-Willi and Angelman Syndrome Molecular Analysis

Prader-Willi and Angelman Syndrome Molecular Analysis

Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are separate neurodevelopmental disorders involving abnormalities in the same region of chromosome 15. The resulting syndrome is largely determined by the parent of origin because the mutation within this region contains imprinted genes. The frequency of PWS and AS in live births is ~1:15,000-1:25,000. PWS is characterized by a two-phase clinical course in individuals. Neonates are hypotonic, poor feeders, fail to thrive, show decreased arousal, and cry weakly. In later infancy or early childhood, individuals exhibit delayed development, excessive eating with a gradual development of obesity, short stature, small hands and feet, and hypogonadism.

Unlike PWS, neonates with AS present normal birth history, no major birth defects, and normal metabolic, chemical, and hematologic profiles. However, developmental delay by 6-12 months is typical for individuals with AS including an absence of speech and severe retardation. AS individuals have unique behavior characterized by a happy demeanor (excitable with frequent smiling and bursts of laughter with minimal stimulus).

The abnormalities involved with PWS and AS cases are caused by either deletions in chromosome 15 (15q11.2-13) or uniparental disomy (UPD). UPD is when both chromosomal pairs are inherited from the same parent, rather than one from each parent. PWS occurs from either a deletion of paternally derived chromosome (~70%), maternal UPD (~25-30%), or an imprinting defect (<5%). AS results from deletion in the maternally derived chromosome (70%), paternal UPD (3-7%), imprinting defect (5%), or mutations in the UBE3A gene (~10%).

Recurrence for PWS and AP due to either deletion in chromosome 15 and UPD is extremely low because these are *de novo* events during conception. However, the possibility of paternal (PWS) or maternal (AS) balanced rearrangement or gonadal mosaicism, and therefore higher risk of recurrence, is less than 1%. Families with a detected imprinting mutation (PWS and AS) or mutations in the UBE3A gene show a 50% risk of recurrence.

PWS and AS detection includes both cytogenetic and molecular approaches aimed at detecting deletions, UPD, or imprinting defects. Cytogenetic analyses include high resolution chromosome analysis, detecting large deletions, translocations, and extra chromosomes, and fluorescence in situ hybridization (FISH), detecting common and typical deletions of the chromosome. Molecular-based DNA methylation analyses (Southern blot and polymerase chain reaction [PCR]) are used to confirm PWS or AS. DNA sequence analysis is available for the detection of mutations in the UBE3A gene for AS.

  • Confirmation of diagnosis of Prader-Willi syndrome
  • Confirmation of diagnosis of Angelman syndrome
  • Prenatal screening for Prader-Willi syndrome and Angelman syndrome

Abnormal methylation pattern is consistent with absence of the paternally derived copy of the PW/AS critical region.

Microdeletion of the PWS/AS critical region (70-75 percent), maternal uniparental disomy of chromosome 15 (25-29 percent), imprinting center defect or balanced chromosome translocation (less than 1 percent)

Microdeletions of the AS/PWS critical region (68 percent), UBE3A mutations (11 percent), paternal uniparental disomy of chromosome 15 (7 percent), imprinting center defects (3 percent), unbalanced chromosome translocation (less than 1 percent), and unknown (10 percent).

Negative for mutation analyzed, or mutations not detected (mutations for Prader-Willi syndrome and Angelman syndrome)

 

 

Cytogenetic analysis:

  • High resolution chromosome analysis
  • Fluorescence in situ hybridization (FISH) testing

DNA methylation analysis:

  • Southern blot analysis
  • Polymerase chain reaction (PCR) for Prader-Willi syndrome and Angelman syndrome

Whole blood (EDTA); Amniotic fluid or chorionic villi (CV).

Stability

  • Ambient: 1-3 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
DNA sequence analysis of *UBE3A* gene.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login